Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement

NEXT STORY
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
PREV STORY
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Bellerophon to Present Results from its Phase 2 iNO-PF Study of INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease at Upcoming Scientific Conferences

author_avatar
NASDAQ Market News

Global Nerve Conduit Market to Reach USD 450 Million by 2028; Use of Nerve Conduit Bridging Technique to Generate Revenue, States Vantage Market Research

author_avatar
NASDAQ Market News

Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group

author_avatar
NASDAQ Market News